Scott: 45 Year Old Male with RA Showing Insignificant Improvement After Initial Treatment

Rheumatology
Curriculum:
Rheumatoid Arthritis: A Clinical Update on the Comparative Effectiveness of Biological DMARDs
Credits:
0.5 AAPA Category 1 Credit(s) 0.5 AMA PRA Category 1 Credit(s)™
Launch Date:
August 19, 2014
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

This activity is intended for rheumatologists involved in the management of patients with moderate to severe rheumatoid arthritis

Relevant Terms:

RA, Rheumatoid Arthritis, Rheumatology

Jonathan Kay, MD

Jonathan Kay, MD
Director of Clinical Research, Division of Rheumatology
Professor of Medicine
University of Massachusetts Medical School
Worcester, MA

Jonathan Kay, MD, received his medical degree from the University of California School of Medicine in San Francisco, California. He then completed an internship and residency at the Hospital of the University of Pennsylvania in Philadelphia and fellowships in rheumatology and immunology at The Brigham and Women's Hospital and Harvard Medical School in Boston, Massachusetts.

Dr. Kay is Professor of Medicine at the University of Massachusetts Medical School and a Physician at UMass Memorial Medical Center in Worcester, where he directs Clinical Research in the Division of Rheumatology.

Dr. Kay is a Fellow of the American College of Rheumatology and of the American College of Physicians. He is an ad hoc reviewer for many journals and a member of the editorial boards of Arthritis Care & Research, Best Practice and Research Clinical Rheumatology, and the Journal of Clinical Rheumatology.  

Dr. Kay's clinical interests span the spectrum of rheumatic diseases, with special interest in rheumatoid arthritis and other forms of inflammatory arthritis. He was a member of the group that developed the 2010 ACR/EULAR Diagnostic and Classification Criteria for Rheumatoid Arthritis.  He chairs the Rheumatology Working Group and is a member of the Internal Medicine and Musculoskeletal Topic Advisory Groups for the World Health Organization in its Revision of the International Classification of Diseases (ICD)-11.

He has been a principal investigator on over 40 clinical trials of novel therapies for rheumatoid arthritis, ankylosing spondylitis, gout, and osteoarthritis. Over the past two decades, his clinical research has focused on nephrogenic systemic fibrosis (formerly known as nephrogenic fibrosing dermopathy), beta2-microglobulin amyloidosis, and other rheumatologic problems of patients with chronic kidney disease. Dr. Kay lectures internationally and is the author of more than 100 publications and book chapters.

Vivian P. Bykerk, BSc, MD, FRCPC

Vivian P. Bykerk, BSc, MD, FRCPC
Director of the Inflammatory Arthritis Center for Excellence
Hospital for Special Surgery
New York, NY

Dr. Vivian Bykerk received both her BSc and Medical degrees from McMaster University in Ontario, Canada, where she also began her residency in internal medicine. She completed this along with a fellowship in critical care medicine at the University of Toronto, and then went on to complete her fellowship at McGill University in Montreal, Quebec, Canada.

Through the years, Dr. Bykerk has been involved in a vast variety and number of extramural professional responsibilities including reviewing & editorial positions, as well as administration, committee, and research positions both at national and international levels.

Currently, Dr. Bykerk is an Associate Attending Physician and Director of the Inflammatory Arthritis Center at the Hospital for Special Surgery, and an Associate Professor of Medicine at Weill Cornell Medical College. Over the past 15 years, Dr. Bykerk has participated in many clinical trials testing new and emerging therapies in rheumatoid arthritis (RA) to include; randomized trials of new agents for the treatment of RA as well as observational studies to confirm real world effectiveness and safety of approved agents.

Today, Dr. Bykerk's primary area of research and knowledge translation focuses on the early diagnosis of RA and optimization of the treatment of early and established RA to ensure the best outcomes for patients. Dr. Bykerk has participated and helped design randomized controlled trials and long term observational studies evaluating real world remission rates in RA.  In particular, Dr. Bykerk is serving as the principle investigator of a multicenter inception cohort study of 2400 patients with early inflammatory and rheumatoid arthritis, initiated in 2006. Additionally, Dr. Bykerk is on the steering committee of the Outcomes Measures in Rheumatology Clinical Trials (OMERACT) Flare group, working with a group of international investigators, to develop a measure of Flare in RA.

Moving forward, Dr. Bykerk is in the process of initiating a large multicenter inception cohort study of patients with new onset RA in the United States. The study will focus on predictors of prognosis to optimize patient outcomes and will provide the infrastructure to test decision aids for patients living with and clinicians treating early RA, while incorporating information from emerging biomarkers.

Elena M. Massarotti, MD

Elena M. Massarotti, MD
Co-Director, Center for Clinical Therapeutics
Rheumatology Director, Clinical Trials
Lupus Center Division of Rheumatology Brigham and Women's Hospital
Boston, MA

Elena Massarotti, MD, practices general rheumatology in the rheumatology division of the Brigham and Women's Hospital, which is a large, full service, tertiary care referral center and a major teaching hospital of Harvard Medical School. This is largely a referral-based practice, comprised of patients referred by primary care physicians, other sub-specialists, and other rheumatologists practicing in the northeastern United States. Dr. Massarotti provides consultation to patients presenting with complex clinical problems, including patients with challenging diagnoses.                                                                                                                 

In Dr. Massarotti's previous role as the clinical director of rheumatology at Tufts New England Medical Center, she was regarded as the senior clinical rheumatologist and oversaw the clinical care delivered in the clinic along with the division chief who identified and managed quality assurance goals (e.g. tracking of adverse events related to joint injections, patient educational materials for new medications) and instituted policies directed at enhancing patient care (e.g. prepared medication information sheets for patients). In 1998, Dr. Massarotti established the annual Merrill Lecture in Clinical Rheumatology at Tufts New England Medical Center with donated funds. This lectureship honored the clinical and translational contributions of outstanding rheumatologists, and was widely attended by the northeastern rheumatology community. In 2000, under the leadership of Dr. Allen Steere (the division chief of rheumatology at Tufts New England Medical Center at that time) Dr. Massarotti helped to design the new outpatient Itzhak Perlman Family Arthritis Treatment Center at Tufts-NEMC, which was a new clinic focused exclusively for patients with rheumatic diseases. From 2000-2003, Dr. Massarotti established "Patient Care Forums", which were faculty led patient seminars that focused on common rheumatic issues and were held during evening hours for patients and family members to attend. Beginning in 2004, Dr. Massarotti helped develop and grow a clinical trials program in the division of rheumatology.

Michael O. Fleming, MD, FAAFP

Michael O. Fleming, MD, FAAFP
Assistant Clinical Professor of Family Medicine and Comprehensive Care
LSU Health Science Center School of Medicine
Shreveport, LA
Assistant Clinical Professor of Family Medicine
Department of Family and Community Medicine, Tulane University Medical School
New Orleans, LA
Chief Medical Officer
Antidote Education Company & Amedisys, Inc.
Dallas, TX

Michael Fleming, MD, serves as founding Director, Chairman and Chief Medical Officer for Antidote Education Company, which provides continuing education for health care providers. He serves as an assistant clinical professor in the Department of Family Medicine at Louisiana State University Health Science Center and in the Department of Family and Community Medicine at Tulane University Medical School. He is Past President of the American Academy of Family Physicians and the Louisiana Academy of Family Physicians, and was founding President of the Louisiana Health Care Quality Forum, a partnership with the State of Louisiana aiming to provide high-quality health care to the state. Dr. Fleming has served as Speaker of the Congress of Delegates of the AAFP and as Board Chair of the AAFP Board of Directors. As an active member of the medical quality field, he serves on various boards and panels for the health information technology industry. Additionally, he participates in international activities promoting medical education and primary care worldwide.
 
Dr. Fleming was honored as Louisiana Family Doctor of the Year in 1996. The LSU Health Science Center presented him with the Family Medicine Award upon graduation in 1975; in 2003 the award was renamed, and is now called the Michael O. Fleming Award in Family Medicine.

Dr. Fleming also serves as the Chief Medical Officer for Amedisys Inc.
1. Summarize the comparative effectiveness trials of biological DMARDs for the treatment of RA
2. Compare and contrast the issues of treatment safety in managing RA
3. Apply the ACR and EULAR guidelines for the appropriate use of biologics to treat patients with RA
4. Construct individual plans to effectively manage patients with RA

Disclosure
Antidote is committed to creating, developing, and operating high-quality, relevant, and practical continuing medical education activities that are in compliance with the ACCME's policies on commercial support and disclosure. Specifically, we are dedicated to ensuring that our activities are planned and implemented free of the control of commercial interests. To this end, Antidote requires everyone who is in a position to influence the content of an activity to disclose all relevant relationships with commercial interests.  Antidote then seeks to resolve these conflicts. Any person who refuses to disclose their relationships, or whose conflicts cannot be resolved may not participate in the activity. In addition, it is our standard practice to disclose all relevant financial relationships of our faculty in writing to our attendees before the beginning of an educational activity.

Antidote also requires that faculty disclose to the participants when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

The planning staff of Antidote Medical Education Company, and RealCME have no commercial relationships to disclose.
 
Individuals in a position to control the content of this activity reported the following relevant financial relationships with commercial interests:
Elena M. Massarotti, MD has disclosed the following relationships:
Consulting Fee(s): Sanofi Aventis, Biogen
Research/Grant(s): Bristol-Myers Squibb, Human Genome Sciences
 
Jonathan Kay, MD has disclosed the following relationships:
Honorarium: Pfizer
Consulting Fee(s): Bristol-Myers Squibb
Research/Grant(s): Abbott Laboratories, Eli Lilly, Pfizer, Sanofi-Aventis
 
Vivian P. Bykerk, BSc, MD, FRCPC has disclosed the following relationships:
Honorarium: Bristol-Myers Squibb
Consulting Fee(s): Amgen, Augurex, Crescendo, Gennentech, Merck, Pfizer, Roche, UCB
Research/Grant(s): Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Gennentech, Johnson & Johnson, Pfizer, Roche, UCB
Other: Data Safety Monitoring Board, Spouse Novartis Employee and owns stock
 
The following individuals have indicated no conflict of interest disclosures to report:
Michael O. Fleming, MD FAAFP (Course Director)
Leigh McKinney (Editor)
Matthew Fleming (Vice President, Antidote Education Company)
 
OFF-LABEL OR INVESTIGATIONAL PRODUCT DISCUSSION
All faculty have indicated that this enduring material does not include the off-label/investigational use of a commercial product or device. 
 
DISCLAIMER
The opinions and recommendations expressed by faculty in this activity are their own and do not necessarily represent the views of Antidote Education Company, and RealCME. Please review complete prescribing information for specific drugs or combination of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.
 
ACCREDITATION STATEMENTS
ACCME: Antidote Education Company is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Antidote designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.50 hours of Category I credit for completing this program.
 
HOW TO RECEIVE CREDIT
There are no fees for participating in and receiving credit for this activity. The participant must read the learning objectives and enduring material and must answer the multiple-choice online post-test. Please complete the evaluation form, which provides each participant with the opportunity to comment on the quality of the instructional process, the perception of enhanced professional effectiveness, the perception of commercial bias, and his/her views on future educational needs. A score of at least 65% is required to successfully complete this activity. The participant may take the test until successfully passed. Credit is available through August 19, 2015.
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above



 
 
Release Date:  August 19, 2014 
Expiration Date:  August 19, 2015
 
COPYRIGHT INFORMATION
Copyright © 2014 Antidote Education Company. All rights reserved. No part of this material may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations.
 
PRIVACY POLICY
Please read Antidote's Privacy Policy at http://www.antidotecme.com/privacypolicy.aspx
If you have questions about this CME activity, please Antidote at 888-692-2631 or registration@antidotecme.com.
 
COMMERCIAL SUPPORT
This activity is made possible by an educational grant from Bristol-Myers Squibb.